All In MedTech

Device Trial Radar · NCT06806332

Glaucoma Drop Aids Part 2

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Boston Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Boston Medical Center Patient Safety Grant
First posted
Feb 4, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Supportive care
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Glaucoma medications are vital to disease management and prevention of further loss of vision as over time glaucoma will lead to irreversible blindness. The average size of a glaucoma medication bottle is around 10cc and these medications when used 2-3 times daily are expected to last patients an entire month. The investigators found that at Boston Medical Center (BMC) a majority of Yawkey Eye Clinic patients are unable to deliver the drops into their eyes due to poor vision or difficulty squeezing drop bottles. These patients also often deliver more than a necessary amount leading to premature completion of the bottle. However, because the cost benefit ratio of these drop aids is unclear, they are not routinely offered to the patients. Although the efficacy of these drop aids has not been well studied, if effective, the cost of these drop aids would more than pay themselves by improving medication compliance and visual function of the patients. This study aims to determine the efficacy of the Nanodropper in the BMC Yawkey Eye Clinic patient population.

Conditions

  • Glaucoma
  • Intraocular Pressure

Interventions

  • NanodropperDevice

    The Nanodropper is the only FDA-listed, volume-reducing adaptor for eyedrop bottles. By twisting the Nanodropper onto a compatible bottle, the drop-size can be reduced by over 60%. Smaller drops have been shown to reduce waste, cost, and side effects.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Completion of topical ophthalmic drug bottleTime frame: 12 weeks
  2. Satisfaction with dispensing opthalmic medicationTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yawkey Eye Clinic, Boston Medical Center

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.